Home Cart Sign in  
Chemical Structure| 66607-26-9 Chemical Structure| 66607-26-9
Chemical Structure| 66607-26-9
Product Citations

Alternative Products

Product Details of [ 66607-26-9 ]

CAS No. :66607-26-9
Formula : C7H5FN2
M.W : 136.13
SMILES Code : FC1=NNC2=C1C=CC=C2
MDL No. :MFCD09909613
InChI Key :PYWAWXBVLNWBDP-UHFFFAOYSA-N
Pubchem ID :5325044

Safety of [ 66607-26-9 ]

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Calculated chemistry of [ 66607-26-9 ] Show Less

Physicochemical Properties

Num. heavy atoms 10
Num. arom. heavy atoms 9
Fraction Csp3 0.0
Num. rotatable bonds 0
Num. H-bond acceptors 2.0
Num. H-bond donors 1.0
Molar Refractivity 36.05
TPSA ?

Topological Polar Surface Area: Calculated from
Ertl P. et al. 2000 J. Med. Chem.

28.68 Ų

Lipophilicity

Log Po/w (iLOGP)?

iLOGP: in-house physics-based method implemented from
Daina A et al. 2014 J. Chem. Inf. Model.

1.1
Log Po/w (XLOGP3)?

XLOGP3: Atomistic and knowledge-based method calculated by
XLOGP program, version 3.2.2, courtesy of CCBG, Shanghai Institute of Organic Chemistry

1.99
Log Po/w (WLOGP)?

WLOGP: Atomistic method implemented from
Wildman SA and Crippen GM. 1999 J. Chem. Inf. Model.

2.12
Log Po/w (MLOGP)?

MLOGP: Topological method implemented from
Moriguchi I. et al. 1992 Chem. Pharm. Bull.
Moriguchi I. et al. 1994 Chem. Pharm. Bull.
Lipinski PA. et al. 2001 Adv. Drug. Deliv. Rev.

1.83
Log Po/w (SILICOS-IT)?

SILICOS-IT: Hybrid fragmental/topological method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

2.5
Consensus Log Po/w?

Consensus Log Po/w: Average of all five predictions

1.91

Water Solubility

Log S (ESOL):?

ESOL: Topological method implemented from
Delaney JS. 2004 J. Chem. Inf. Model.

-2.6
Solubility 0.339 mg/ml ; 0.00249 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (Ali)?

Ali: Topological method implemented from
Ali J. et al. 2012 J. Chem. Inf. Model.

-2.22
Solubility 0.823 mg/ml ; 0.00605 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble
Log S (SILICOS-IT)?

SILICOS-IT: Fragmental method calculated by
FILTER-IT program, version 1.0.2, courtesy of SILICOS-IT, http://www.silicos-it.com

-3.16
Solubility 0.0944 mg/ml ; 0.000693 mol/l
Class?

Solubility class: Log S scale
Insoluble < -10 < Poorly < -6 < Moderately < -4 < Soluble < -2 Very < 0 < Highly

Soluble

Pharmacokinetics

GI absorption?

Gatrointestinal absorption: according to the white of the BOILED-Egg

High
BBB permeant?

BBB permeation: according to the yolk of the BOILED-Egg

Yes
P-gp substrate?

P-glycoprotein substrate: SVM model built on 1033 molecules (training set)
and tested on 415 molecules (test set)
10-fold CV: ACC=0.72 / AUC=0.77
External: ACC=0.88 / AUC=0.94

No
CYP1A2 inhibitor?

Cytochrome P450 1A2 inhibitor: SVM model built on 9145 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.83 / AUC=0.90
External: ACC=0.84 / AUC=0.91

Yes
CYP2C19 inhibitor?

Cytochrome P450 2C19 inhibitor: SVM model built on 9272 molecules (training set)
and tested on 3000 molecules (test set)
10-fold CV: ACC=0.80 / AUC=0.86
External: ACC=0.80 / AUC=0.87

No
CYP2C9 inhibitor?

Cytochrome P450 2C9 inhibitor: SVM model built on 5940 molecules (training set)
and tested on 2075 molecules (test set)
10-fold CV: ACC=0.78 / AUC=0.85
External: ACC=0.71 / AUC=0.81

No
CYP2D6 inhibitor?

Cytochrome P450 2D6 inhibitor: SVM model built on 3664 molecules (training set)
and tested on 1068 molecules (test set)
10-fold CV: ACC=0.79 / AUC=0.85
External: ACC=0.81 / AUC=0.87

No
CYP3A4 inhibitor?

Cytochrome P450 3A4 inhibitor: SVM model built on 7518 molecules (training set)
and tested on 2579 molecules (test set)
10-fold CV: ACC=0.77 / AUC=0.85
External: ACC=0.78 / AUC=0.86

No
Log Kp (skin permeation)?

Skin permeation: QSPR model implemented from
Potts RO and Guy RH. 1992 Pharm. Res.

-5.72 cm/s

Druglikeness

Lipinski?

Lipinski (Pfizer) filter: implemented from
Lipinski CA. et al. 2001 Adv. Drug Deliv. Rev.
MW ≤ 500
MLOGP ≤ 4.15
N or O ≤ 10
NH or OH ≤ 5

0.0
Ghose?

Ghose filter: implemented from
Ghose AK. et al. 1999 J. Comb. Chem.
160 ≤ MW ≤ 480
-0.4 ≤ WLOGP ≤ 5.6
40 ≤ MR ≤ 130
20 ≤ atoms ≤ 70

None
Veber?

Veber (GSK) filter: implemented from
Veber DF. et al. 2002 J. Med. Chem.
Rotatable bonds ≤ 10
TPSA ≤ 140

0.0
Egan?

Egan (Pharmacia) filter: implemented from
Egan WJ. et al. 2000 J. Med. Chem.
WLOGP ≤ 5.88
TPSA ≤ 131.6

0.0
Muegge?

Muegge (Bayer) filter: implemented from
Muegge I. et al. 2001 J. Med. Chem.
200 ≤ MW ≤ 600
-2 ≤ XLOGP ≤ 5
TPSA ≤ 150
Num. rings ≤ 7
Num. carbon > 4
Num. heteroatoms > 1
Num. rotatable bonds ≤ 15
H-bond acc. ≤ 10
H-bond don. ≤ 5

1.0
Bioavailability Score?

Abbott Bioavailability Score: Probability of F > 10% in rat
implemented from
Martin YC. 2005 J. Med. Chem.

0.55

Medicinal Chemistry

PAINS?

Pan Assay Interference Structures: implemented from
Baell JB. & Holloway GA. 2010 J. Med. Chem.

0.0 alert
Brenk?

Structural Alert: implemented from
Brenk R. et al. 2008 ChemMedChem

0.0 alert: heavy_metal
Leadlikeness?

Leadlikeness: implemented from
Teague SJ. 1999 Angew. Chem. Int. Ed.
250 ≤ MW ≤ 350
XLOGP ≤ 3.5
Num. rotatable bonds ≤ 7

No; 1 violation:MW<1.0
Synthetic accessibility?

Synthetic accessibility score: from 1 (very easy) to 10 (very difficult)
based on 1024 fragmental contributions (FP2) modulated by size and complexity penaties,
trained on 12'782'590 molecules and tested on 40 external molecules (r2 = 0.94)

1.8

Application In Synthesis of [ 66607-26-9 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 66607-26-9 ]

[ 66607-26-9 ] Synthesis Path-Downstream   1~6

  • 1
  • [ 5750-76-5 ]
  • [ 66607-26-9 ]
  • 1-(2-chloropyrimidin-4-yl)-3-fluoro-1H-indazole [ No CAS ]
YieldReaction ConditionsOperation in experiment
A solution of 3-flouroindazole (680.5 mg, 5.0 mmol) in dry DMF (15 mL) cooled to 0 C is treated with NaH (200 mg, 5.0 mmol, 60% in mineral oil). After stirring at 25 C for 2 h the mixture is cooled to 0 C and 2,4,5-trichloropyrimidine (917 mg, 5.0 mmol) is added. After stirring for 4 h the mixture is quenched with water (50 mL) and extracted with ethyl acetate (3 x 25 mL), washed with water (2 x 25 mL) and saturated brine (25 mL), and dried over MgSO4. The solvent is removed under reduced pressure, and the residue is purified by column chromatography (Pet/EtOAc 20/1) to afford 1-(2-chloropyrimidin-4-yl)-<strong>[66607-26-9]3-fluoro-1H-indazole</strong> as a white solid.
  • 2
  • [ 5750-76-5 ]
  • [ 66607-26-9 ]
  • 1-(2,5-dichloropyrimidin-4-yl)-3-fluoro-1H-indazole [ No CAS ]
YieldReaction ConditionsOperation in experiment
A solution of 3-fluoroindazole (680.5 mg, 5.0 mmol) in dry DMF (15 mL) cooled to 0 C is treated with NaH (200 mg, 5.0 mmol, 60% in mineral oil). After stirring at 25 C for 2 h the mixture is cooled to 0 C and 2,4,5-trichloropyrimidine (917 mg, 5.0 mmol) is added. After stirring for 4 h the mixture is quenched with water (50 mL) and extracted with ethyl acetate (3 x 25 mL), washed with water (2 x 25 mL) and saturated brine (25 mL), and dried over MgSO4. The solvent is removed under reduced pressure, and the residue is purified by column chromatography (Pet/EtOAc 20/1) to afford 1-(2,5-dichloropyrimidin-4-yl)-<strong>[66607-26-9]3-fluoro-1H-indazole</strong> as a white solid.
  • 3
  • [ 3177-24-0 ]
  • [ 66607-26-9 ]
  • 1-(2-chloro-5-cyanopyrimidin-4-yl)-3-fluoro-1H-indazole [ No CAS ]
YieldReaction ConditionsOperation in experiment
A solution of 3-fluoroindazole (680.5 mg, 5.0 mmol) in dry DMF (15 mL) cooled to 0 C is treated with NaH (200 mg, 5.0 mmol, 60percent in mineral oil). After stirring at 25 C for 2 h the mixture is cooled to 0 C and <strong>[3177-24-0]2,4-dichloro-5-cyanopyrimidine</strong> (870 mg, 5.0 mmol) is added. After stirring for 4 h the mixture is quenched with water (50 mL) and extracted with ethyl acetate (3 x 25 mL), washed with water (2 x 25 mL) and saturated brine (25 mL), and dried over MgSO4. The solvent is removed under reduced pressure, and the residue is purified by column chromatography (Pet/EtOAc 20/1) to afford the 1-(2-chloro-5- cyanopyrimidin-4-yl)-3-fluoro-1H-indazole as a white solid.
  • 4
  • [ 3932-97-6 ]
  • [ 66607-26-9 ]
  • 1-(2-chloro-5-trifluoromethylpyrimidin-4-yl)-3-fluoro-1H-indazole [ No CAS ]
YieldReaction ConditionsOperation in experiment
A solution of 3-fluoroindazole (680.5 mg, 5.0 mmol) in dry DMF (15 mL) cooled to 0 C is treated with NaH (200 mg, 5.0 mmol, 60% in mineral oil). After stirring at 25 C for 2 h the mixture is cooled to 0 C and 2,4-dichloro-5-trifluoromethylpyrimidine (1.085 g, 5.0 mmol) is added. After stirring for 4 h the mixture is quenched with water (50 mL) and extracted with ethyl acetate (3 x 25 mL), washed with water (2 x 25 mL) and saturated brine (25 mL), and dried over MgSO4. The solvent is removed under reduced pressure, and the residue is purified by column chromatography (Pet/EtOAc 20/1) to afford the 1-(2-chloro-5-trifluoromethylpyrimidin-4-yl)-<strong>[66607-26-9]3-fluoro-1H-indazole</strong> as a white solid.
  • 6
  • 4-chloro-N-(4-fluoro-2-methoxy-5-nitrophenyl)-1,3,5-triazin-2-amine [ No CAS ]
  • [ 66607-26-9 ]
  • C17H11F2N7O3 [ No CAS ]
YieldReaction ConditionsOperation in experiment
With potassium carbonate; In acetonitrile; at 20℃; Compound 13-1 (200 mg, 1.47 mmol) and Compound 13-2 (420 mg, 1.40 mmol) are dissolved in CH3CN (20 ml), then adding K2CO3 (386.7 mg, 2.80 mmol) and stirring at room temperature overnight. The reaction progress is detected by LC-MS. After the reaction is completed, water is added for quenching, then extracting with ethyl acetate (50 ml × 3), drying over anhydrous sodium sulfate; and a crude product Compound 13-3 is obtained by rotary drying.
 

Historical Records

Technical Information

Categories

Related Functional Groups of
[ 66607-26-9 ]

Fluorinated Building Blocks

Chemical Structure| 885271-64-7

A162590 [885271-64-7]

5-(Trifluoromethyl)-1H-indazole

Similarity: 0.82

Chemical Structure| 885522-09-8

A266932 [885522-09-8]

4-Fluoro-6-methyl-1H-indazole

Similarity: 0.78

Chemical Structure| 885520-26-3

A106269 [885520-26-3]

4,6-Difluoro-1H-indazole

Similarity: 0.77

Chemical Structure| 885520-07-0

A165624 [885520-07-0]

4-Fluoro-1H-indazol-6-amine

Similarity: 0.77

Chemical Structure| 885694-00-8

A101035 [885694-00-8]

7-(Trifluoromethyl)-1H-indazole

Similarity: 0.74

Related Parent Nucleus of
[ 66607-26-9 ]

Indazoles

Chemical Structure| 885271-64-7

A162590 [885271-64-7]

5-(Trifluoromethyl)-1H-indazole

Similarity: 0.82

Chemical Structure| 885522-09-8

A266932 [885522-09-8]

4-Fluoro-6-methyl-1H-indazole

Similarity: 0.78

Chemical Structure| 885520-26-3

A106269 [885520-26-3]

4,6-Difluoro-1H-indazole

Similarity: 0.77

Chemical Structure| 885520-07-0

A165624 [885520-07-0]

4-Fluoro-1H-indazol-6-amine

Similarity: 0.77

Chemical Structure| 271-44-3

A255384 [271-44-3]

1H-Indazole

Similarity: 0.75